The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats

Brain Res. 1996 Aug 5;729(1):124-6.

Abstract

Intracranial microdialysis was utilized to assess the effects of the novel neurotensin antagonist SR 48692 on extracellular gamma-amino-butyric acid (GABA) and glycine in the striatum. Subcutaneous injection of SR 48692 (0.2 mg/kg) significantly decreased extracellular striatal GABA levels, with peak decreases occurring 2-3 h post-injection. Injection of SR 48692 had no significant effect on glycine levels. These data suggest that endogenous neurotensin may modulate striatal GABA levels.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analysis of Variance
  • Animals
  • Corpus Striatum / drug effects*
  • Corpus Striatum / metabolism
  • Female
  • Glycine / metabolism
  • Injections, Subcutaneous
  • Microdialysis
  • Pyrazoles / pharmacology*
  • Quinolines / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Neurotensin / antagonists & inhibitors*
  • gamma-Aminobutyric Acid / metabolism*

Substances

  • Pyrazoles
  • Quinolines
  • Receptors, Neurotensin
  • SR 48692
  • gamma-Aminobutyric Acid
  • Glycine